Neurodegenerative Diseases: Current Research

Programmed Cell Death 4: A New Target for Antidepressant Research

Yufeng Jia^1,2, Yuan Li^1,3 * and Lining Zhang¹*

¹Shandong Key Laboratory of Infection and Immunity, Department of Immunology, School of Basic Medical Sciences, Shandong University, Jinan, Shandong, 250021, China.
²Department of Pathogen Biology, School of Basic Medical Sciences, Capital Medical University, Beijing,100069, China.
³Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China.

Abstract

Depression is a widespread and serious global mental illness. Approximately 322 million people worldwide suffer from depression, which accounts for 4.4% of the total population. Currently, antidepressants are the preferred treatment for depression. However, clinical antidepressants such as selective 5-hydroxytryptamine reuptake inhibitors (SSRIs), and norepinephrine reuptake inhibitors (SNRIs) are commonly associated with serious side effects. As a result, it is crucial to explore new therapeutic targets for the treatment of depression. Our results indicate that Programmed Cell Death 4 (PDCD4) is an effective antidepressant target,
which holds important implications in the development of antidepressant drugs.

Keywords: